文献速递外周动脉疾病

股腘动脉螺旋编织镍钛支架的中期疗效分析

A midterm analysis of patients who received femoropopliteal helical interwoven nitinol stents.
PubMed 文献 · J Vasc Surg · 2020-02-17

本研究回顾性分析315例(360条患肢)接受股腘动脉螺旋编织镍钛支架(Supera)治疗的患者,随访至72个月。总体一期通畅率在6、12、24、36、48、60、72个月分别为90.6%、80.5%、73.8%、68.9%、65.3%、63.1%、63.1%。支架长度和腘动脉受累是通畅率变差的显著因素,无支架断裂,无手术或器械相关死亡。

要点

  • Supera支架在股腘动脉病变中远期通畅率良好,72个月达63.1%。
  • 支架长度和腘动脉受累显著降低通畅率(P=.011和P=.005)。
  • 随访中无支架断裂,无手术或器械相关并发症。

核心结论

  • Supera螺旋编织镍钛支架在股腘动脉病变中有效且耐久,中期通畅率可接受。

研究设计与样本

  • 回顾性分析前瞻性收集的315例患者(198例男性,360条患肢)数据,中位年龄78岁(范围46-100岁)。

主要发现

  • 总体一期通畅率在6、12、24、36、48、60、72个月分别为90.6%、80.5%、73.8%、68.9%、65.3%、63.1%、63.1%。
  • 踝肱指数从术前0.58±0.18增至术后0.87±0.16。
  • 随访期间无支架断裂,无手术或器械相关发病率或死亡率,血运重建后9例大截肢。

关键数值与推荐

  • 再狭窄定义为超声显示靶病变再狭窄≥50%。
  • 支架长度和腘动脉受累与通畅率显著变差相关(log-rank检验,P=.011和P=.005)。
  • 4mm内径支架初始通畅率低于5mm支架,但46个月时通畅率合并交叉(log-rank检验,P=.131)。

临床怎么用

  • 对于股腘动脉病变,Supera支架可作为治疗选择,尤其适用于长病变和腘动脉段。
  • 需关注支架长度和腘动脉受累对通畅率的影响,加强随访。

局限性

  • 回顾性分析,可能存在选择偏倚。
  • 非药物洗脱支架,未与其他支架或药物涂层球囊直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study was to report midterm outcomes (up to 72 months) of patients who received femoropopliteal helical interwoven nitinol stents (Supera Peripheral Stent System, Abbott Laboratories, Inc, Webster, Tex). METHODS: Prospectively collected data on patients treated with femoropopliteal non-drug-eluting angioplasty and helical interwoven nitinol stents were retrospectively analyzed. Patients were followed up with 6, 12, 18, 24, 36, 48, 60, and 72 months clinical, duplex, and radiographic assessments. Restenosis is defined as 50% or greater restenosis of the target lesion on duplex ultrasound imaging. RESULTS: From October 2011 to September 2018, 315 patients (198 males) with 360 legs and a median age of 78 years (range, 46-100 years) were included. Symptoms of claudication, rest pain, and tissue loss were found in 212 (58.9%), 53 (14.7%), and 150 (41.7%) legs, respectively. In 176 (48.9%) legs, stents were placed in the popliteal segments. The mean stented lesion length was 119.0 mm (range, 40-450 mm). The overall primary patency rates at 6, 12, 24, 36, 48, 60, and 72 months were 90.6%, 80.5%, 73.8%, 68.9%, 65.3%, 63.1%, and 63.1%, respectively. The ankle-brachial pressure index increased from 0.58 ± 0.18 preoperatively to 0.87 ± 0.16 postoperatively. There were no stent fractures on follow-up. Patency rate was not statistically affected by indication of treatment, lesion calcification, or diabetes, but the length of stents and involvement of popliteal arteries were statistically significantly worse (log-rank test, P = .011 and P = .005). Stents with inner diameters of 4-mm had an initial lower patency compared with 5-mm stents, but the patency rates merged and crossed over at 46 months (log-rank test, P = .131). There was no procedural- or device-related morbidity or mortality, and there were nine major amputations after revascularization. CONCLUSIONS: This study provides long-term clinical data demonstrating that Supera stents are effective and durable.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Chan YC, Cheng SW, Cheung GC, et al. A midterm analysis of patients who received femoropopliteal helical interwoven nitinol stents. J Vasc Surg. 2020. PMID: 32081479. doi:10.1016/j.jvs.2019.08.284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。